Paul Tudor Jones Cytokinetics Inc Transaction History

Tudor Investment Corp Et Al

$19.2 Billion
Q2 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Cytokinetics Inc stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 74,989 shares of CYTK stock, worth $3.95 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

74,989

Previous 75,736 0.99%

Holding current value

$3.95 Million

Previous $5.31 Million 23.49%

% of portfolio

0.02%

Previous 0.03%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$47.86 - $75.05 $35,751 - $56,062	-747 Reduced 0.99%	74,989 $4.06 Million
Q1 2024 May 15, 2024	BUY	$63.75 - $108.06 $2.55 Million - $4.32 Million	40,009 Added 111.99%	75,736 $5.31 Million
Q4 2023 Feb 14, 2024	BUY	$26.88 - $83.49 $960,341 - $2.98 Million	35,727 New	35,727 $2.98 Million
Q1 2023 May 15, 2023	BUY	$33.36 - $45.71 $462,970 - $634,363	13,878 Added 75.58%	32,241 $1.14 Million
Q4 2022 Feb 14, 2023	SELL	$35.77 - $51.11 $1.63 Million - $2.33 Million	-45,495 Reduced 71.24%	18,363 $841,000
Q3 2022 Nov 14, 2022	BUY	$38.54 - $54.52 $1.28 Million - $1.81 Million	33,154 Added 107.98%	63,858 $3.09 Million
Q2 2022 Aug 15, 2022	BUY	$33.93 - $48.92 $1.04 Million - $1.5 Million	30,704 New	30,704 $1.21 Million
Q3 2021 Nov 15, 2021	SELL	$18.54 - $35.74 $450,837 - $869,089	-24,317 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$19.79 - $26.99 $424,990 - $579,610	-21,475 Reduced 46.9%	24,317 $481,000
Q1 2021 May 17, 2021	BUY	$18.57 - $25.68 $850,357 - $1.18 Million	45,792 New	45,792 $1.07 Million

Others Institutions Holding CYTK

# of Institutions

406

Shares Held

126M

Call Options Held

3.29M

Put Options Held

2.01M

View Full List

About CYTOKINETICS INC

Ticker CYTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,144,096
Market Cap $4.96B
Description
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...

More about CYTK

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account